Telehealth policy changes, rapid mobile technology developments, and consumer demand for virtual behavioral health services are driving a proliferation of digital behavioral health services, including virtual service delivery platforms and mHealth applications, which includes FDA-approved digital therapeutics. These digital services are reshaping the behavioral health treatment landscape in the U.S. Venture capital-backed digital platforms like Spring Health ($2bn) now deliver therapy as well as medication prescribing. This webinar will bring together academic, business, and industry leaders to discuss the evolution of this industry, its efficacy, and what is in store for the future.
Panelists:
Steve Blumenfield is Head of Partnerships and Alliances for WTW, a global leader in managing people, risk and capital to propel the world’s leading businesses forward. As a key component of WTW’s Innovation and Acceleration capability, Steve’s team looks for inorganic opportunities to solve organic problems for WTW clients. In prior WTW roles Steve has served as the Head of Strategy and Innovation for Health and Benefits, North America and as a Strategy Consultant and Pharmaceuticals Industry Practice leader. Steve has also held roles as Chief Marketing Officer for Prime Therapeutics and Vice President, National Businesses Marketing for Aetna. He is the host of the Cure for the Common Co Podcast, which interviews entrepreneurs in the employer sponsored benefits place.
Adam Chekroud, PhD, is President and Co-founder of Spring Health, based in New York City, and an Assistant Professor of Psychiatry at Yale University. His research seeks to improve treatment outcomes in mental health, and has been featured in the Lancet, JAMA Psychiatry, Lancet Psychiatry, and PNAS, and covered in the Wall Street Journal, Financial Times, BBC, CNN, and NPR.
Lisa Marsch, PhD, is Director of the Dartmouth Center for Technology and Behavioral Health, a designated “Center of Excellence” supported by the National Institute on Drug Abuse at the National Institutes of Health. She is also the Director of the Northeast Node of the National Drug Abuse Clinical Trials Network based out of Dartmouth and the Andrew G. Wallace Professor within the Department of Psychiatry at the Geisel School of Medicine at Dartmouth College. And she leads a national “Science of Behavior Change” initiative supported by the National Institutes of Health with partners at Dartmouth, Stanford, Arizona State University, Drexel, and MIT.
Moderators:
Matthew Eisenberg, PhD, is an Associate Professor at Johns Hopkins Bloomberg School of Public Health. He is also a member of the HBHI Leadership Team.
Beth McGinty, PhD, MS, is Chief of the Division of Health Policy and Economics and Livingston Farrand Professor of Public Health at Weill Cornell Medicine. She is also an HBHI Affiliate Scholar.
Co-sponsor: Center for Mental Health and Addiction Policy
Conversations on the Business of Health Webinar Series
This event is part of a larger series on 'Conversations on the Business of Health,' which will be one-hour webinars that will engage leaders in business and academia. We will explore questions such as: Should companies invest in their employees’ health? Are companies responsible for the health consequences of their products? Will artificial intelligence actually advance health? How can business offer healthcare in novel settings?
Moderated by faculty members and jointly hosted by the Bloomberg School of Public Health, the Carey Business School, the School of Nursing, and the School of Medicine, the series is open to all. Indeed, we invite you to spread the word as we seek participants both inside and outside of Johns Hopkins, including the business world.
Seminars will be on a Friday from noon to 1 p.m. unless otherwise noted.
